Gemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter study


Creative Commons License

Inal A., Kos F. T. , Algin E., Yildiz R., Dikiltas M., Unek I. T. , ...More

NEOPLASMA, vol.59, no.3, pp.297-301, 2012 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 59 Issue: 3
  • Publication Date: 2012
  • Doi Number: 10.4149/neo_2012_038
  • Title of Journal : NEOPLASMA
  • Page Numbers: pp.297-301
  • Keywords: advanced pancreatic cancer, first-line chemotherapy, gemcitabine, cisplatin, RANDOMIZED PHASE-III, CANCER, SURVIVAL

Abstract

The majority of patients with pancreatic cancer is of advanced disease. Several randomized Phase II and III trials suggest that the combination of gemcitabine and cisplatin (GemCis) response rates were higher than Gemcitabine (Gem) alone, however the trials were not enough powered to indicate a statistically significant prolongation of survival in patients with advanced pancreatic adenocarcinoma. The aim of this retrospective multicenter study is to evaluated the efficiency of Gem alone versus GemCis in patients with locally advanced and/or metastatic pancreatic adenocarcinoma.